Modulation of the proteolytic cascade systems by high dose corticosteroids.
The effects of high-dose corticosteroids (HDC) on activities within the proteolytic cascade systems were studied in vitro and in vivo using chromogenic peptide substrate assays. In in vitro experiments 20 mg methylprednisolone sodium succinate (Solu-Medrol) per ml plasma significantly inhibited activation of plasma prekallikrein, prothrombin and plasminogen and reduced functional plasma kallikrein inhibition, antithrombin and antiplasmin activities. The effects of HDC on activities within these proteolytic cascade systems were further evaluated in experimental acute pancreatitis in pigs. Acute pancreatitis was induced by injection of Na-taurocholate into the pancreatic duct. Seven test animals received methylprednisolone sodium succinate 30 mg per kg intravenously for 30 minutes before the induction of pancreatitis as pretreatment. Eight animals remained untreated. Trypsin (TRY), plasma prekallikrein (PKK), plasma kallikrein (KK) and functional plasma kallikrein inhibition capacity (KKI) were studied in the peritoneal exudate. Cardiac output (CO) and mean arterial pressure (MAP) were monitored regularly before and during a 6 hour observation period. During untreated pancreatitis a reduction of PKK levels of about 40% were found, paralleled by an increased KK activity and a reduction of KKI capacity. Several of the animals experienced high TRY activities. The mortality rate was 63% (5 out of 8 animals). In the pretreated groups, all animals survived the observation period. CO and MAP were significantly less reduced than the untreated group at 6 hours. HDC was also found to reduce significantly plasma kallikrein activities in the peritoneal exudate compared with untreated animals. No changes in TRY activities were found in pretreated animals. Furthermore, plasma prekallikrein and functional plasma kallikrein inhibition values in the exudate were elevated significantly in HDC treated animals compared with untreated animals.
D000818:Animals; D000990:Antithrombin III / Q000378:metabolism; D001202:Ascitic Fluid / Q000378:metabolism; D001779:Blood Coagulation Factors / Q000032:analysis*; D005342:Fibrinolysis / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007610:Kallikreins / Q000378:metabolism*; D007705:Kinins / Q000378:metabolism*; D008775:Methylprednisolone / Q000031:analogs & derivatives*; D008776:Methylprednisolone Hemisuccinate / Q000494:pharmacology*; D010195:Pancreatitis / Q000139:chemically induced / Q000378:metabolism*; D010958:Plasminogen / Q000378:metabolism; D011288:Prekallikrein / Q000096:biosynthesis; D011516:Prothrombin / Q000378:metabolism; D013552:Swine; D014357:Trypsin / Q000378:metabolism; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D001779:Blood Coagulation Factors; D007705:Kinins; D000979:alpha-2-Antiplasmin; D008776:Methylprednisolone Hemisuccinate; D000990:Antithrombin III; D011516:Prothrombin; D010958:Plasminogen; D011288:Prekallikrein; D007610:Kallikreins; D014357:Trypsin; D008775:Methylprednisolone